Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells

Grunt,Thomas W.; Wagner,Renate; Ries,Alexander; Berghoff,Anna S.; Preusser,Matthias; Grusch,Michael; Valent,Peter

doi:10.3892/ijo.2024.5612

Targeting endogenous fatty acid synthesis stimulates the migration of ovarian cancer cells to adipocytes and promotes the transport of fatty acids from adipocytes to cancer cells

Authors:
- Thomas W. Grunt
- Renate Wagner
- Alexander Ries
- Anna S. Berghoff
- Matthias Preusser
- Michael Grusch
- Peter Valent
View Affiliations

Affiliations: Cell Signaling and Metabolism Networks Program, Division of Oncology, Department of Medicine I, Medical University of Vienna, A-1090 Vienna, Austria, Comprehensive Cancer Center, Medical University of Vienna, A-1090 Vienna, Austria, Division of Oncology, Department of Medicine I, Medical University of Vienna, A-1090 Vienna, Austria
Published online on: January 11, 2024 https://doi.org/10.3892/ijo.2024.5612
Article Number: 24
Copyright: © Grunt et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite significant advances in oncology, 1 of 108 female patients succumb to ovarian cancer (OC) each year. Improved novel treatments against this aggressive disease would be a major improvement. The growth of OC cells has been demonstrated to be highly dependent on lipids. OC cells are abundantly present in the abdominal cavity and omentum, the main sites of OC expansion. Accordingly, it has been attempted not only to block the hyperactive synthesis of fatty acids (FAs) in cancer cells, but also to disrupt lipid supply. While either strategy has yielded promising results as monotherapy, the induction of resistance pathways diminishing the anticancer effects is yet conceivable. The endogenous regulation of lipid biosynthesis in OC has been extensively studied. However, the role of stromal cells in the modulation of the effects of anti‑lipogenic drugs has not yet been well documented. The present study thus examined the interaction between OC cells and associated stromal cells, when de novo FA synthesis was blocked. It has recently been revealed by the authors that when FA are provided to OC cells in monoculture, the lipid deficiency induced by pharmacological inhibition of FA synthase (FASN), the key enzyme of endogenous FA synthesis, cannot be compensated through an increased FA uptake by OC cells. In the present study, OC cells were co‑cultured with adipocytes preloaded with fluorescent FA and the effects of FASN‑inhibition on OC homing to adipocytes and the transcellular delivery of fluorescent FA from adipocytes to OC cells were examined. The FASN inhibitors, G28UCM and Fasnall, stimulated the spontaneous migration of A2780 OC cells in a concentration‑dependent manner and stimulated the transfer of FA from adipocytes to OC cells. Similar effects were observed with all types of adipocytes tested. The models applied in the present study demonstrated that co‑cultured cancer‑associated adipocytes may attenuate the anticancer effects of FASN inhibitors by attracting tumor cells and by supplying the cells with FA. This lipid‑mediated dependency may provide a rationale for the design of new treatment approaches for the treatment of OC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar
2	American Cancer Society: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html retrieved on 23.12.09.
3	Lee MI, Jung YJ, Kim DI, Paik HJ, Lee S, Jung CS, Kim JY and Kim HY: Metastasis to breast from ovarian cancer and primary ovarian cancer concurrently diagnosis. Gland Surg. 10:1806–1811. 2021. View Article : Google Scholar : PubMed/NCBI
4	Schulenburg A, Brämswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, et al: Neoplastic stem cells: Current concepts and clinical perspectives. Crit Rev Oncol Hematol. 76:79–98. 2010. View Article : Google Scholar : PubMed/NCBI
5	Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, et al: Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 8:e818592013. View Article : Google Scholar : PubMed/NCBI
6	Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST and Mok SC: Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. Am J Physiol Cell Physiol. 309:C444–C4456. 2015. View Article : Google Scholar : PubMed/NCBI
7	Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, Franco W, Scarcelli G, Polacheck WJ, Roque DM, et al: Malignant ascites in ovarian cancer: Cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel). 13:43182021. View Article : Google Scholar : PubMed/NCBI
8	Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 17:1498–1503. 2011. View Article : Google Scholar : PubMed/NCBI
9	Grunt TW: Interacting Cancer Machineries: Cell signaling, lipid metabolism, and epigenetics. Trends Endocrinol Metab. 29:86–98. 2018. View Article : Google Scholar
10	Scaglia N, Frontini-López YR and Zadra G: Prostate cancer progression: As a matter of fats. Front Oncol. 11:7198652021. View Article : Google Scholar : PubMed/NCBI
11	Hao Y, Yi Q, XiaoWu X, WeiBo C, GuangChen Z and XueMin C: Acetyl-CoA: An interplay between metabolism and epigenetics in cancer. Front Mol Med. 2:10445852022. View Article : Google Scholar
12	Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Ogishima J, et al: Detachment from the primary site and suspension in ascites as the initial step in metabolic reprogramming and metastasis to the omentum in ovarian cancer. Oncol Lett. 15:1357–1361. 2018.PubMed/NCBI
13	Chen RR, Yung MMH, Xuan Y, Zhan S, Leung LL, Liang RR, Leung THY, Yang H, Xu D, Sharma R, et al: Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Commun Biol. 2:2812019. View Article : Google Scholar : PubMed/NCBI
14	Grunt TW, Slany A, SemkovaM, Colomer R, López-Rodrı́guez ML, Wuczkowski M, Wagner R, Gerner C and Stübiger G: Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: A multi-omics analysis in ovarian cancer. Sci Rep. 10:148772020. View Article : Google Scholar : PubMed/NCBI
15	Lemberger L, Wagner R, Heller G, Pils D and Grunt TW: Pharmacological inhibition of lipid import and transport proteins in ovarian Cancer. Cancers (Basel). 14:60042022. View Article : Google Scholar : PubMed/NCBI
16	Ji Z, Shen Y, Feng X, Kong Y, Shao Y, Meng J, Zhang X and Yang G: Deregulation of lipid metabolism: The critical factors in ovarian cancer. Front Oncol. 10:5930172020. View Article : Google Scholar : PubMed/NCBI
17	Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A and Testa JR: Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 24:3574–3582. 2005. View Article : Google Scholar : PubMed/NCBI
18	Wagner R, Stübiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, Weghuber J, Karteris E, Nowikovsky K, Wilfinger-Lutz N, Singer CF, et al: Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. Oncotarget. 8:11600–11613. 2017. View Article : Google Scholar : PubMed/NCBI
19	Tomek K, Wagner R, Varga F, Singer CF, Karlic H and Grunt TW: Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res. 9:1767–1779. 2011. View Article : Google Scholar : PubMed/NCBI
20	Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, et al: Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. Int J Cancer. 136:2078–2090. 2015. View Article : Google Scholar
21	Grunt TW, Lemberger L, Colomer R, López Rodríguez ML and Wagner R: The pharmacological or genetic blockade of endogenous de novo fatty acid synthesis does not increase the uptake of exogenous lipids in ovarian cancer cells. Front Oncol. 11:6108852021. View Article : Google Scholar : PubMed/NCBI
22	Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC and Lupu R: Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun. 385:454–459. 2009. View Article : Google Scholar : PubMed/NCBI
23	Yang CS, Matsuura K, Huang NJ, Robeson AC, Huang B, Zhang L and Kornbluth S: Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death. Oncogene. 34:3264–3272. 2015. View Article : Google Scholar :
24	Zhao G, Cardenas H and Matei D: Ovarian Cancer-Why Lipids Matter. Cancers (Basel). 26:18702019. View Article : Google Scholar
25	Gálvez BG, San Martín N and Rodríguez C: TNF-alpha is required for the attraction of mesenchymal precursors to white adipose tissue in Ob/ob mice. PLoS One. 4:e44442009. View Article : Google Scholar : PubMed/NCBI
26	Drury J, Rychahou PG, He D, Jafari N, Wang C, Lee EY, Weiss HL, Evers BM and Zaytseva YY: Inhibition of fatty acid synthase upregulates expression of CD36 to sustain proliferation of colorectal cancer cells. Front Oncol. 10:11852020. View Article : Google Scholar : PubMed/NCBI
27	Dai JM, Sun K, Li C, Cheng M, Guan JH, Yang LN and Zhang LW: Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α. Clin Transl Oncol. 25:1606–1616. 2023. View Article : Google Scholar : PubMed/NCBI
28	Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, et al: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 216:688–703. 2019. View Article : Google Scholar : PubMed/NCBI
29	Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, et al: Adipocyte lipolysis links obesity to breast cancer growth: Adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 5:12017. View Article : Google Scholar : PubMed/NCBI
30	Grunt TW, Somay C, Oeller H, Dittrich E and Dittrich C: Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci. 103:501–509. 1992. View Article : Google Scholar : PubMed/NCBI
31	Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich C and Grunt TW: Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. Br J Cancer. 68:530–536. 1993. View Article : Google Scholar : PubMed/NCBI
32	Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, Inglés-Prieto Á and Janovjak H: Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. EMBO J. 33:1713–1726. 2014. View Article : Google Scholar : PubMed/NCBI
33	Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, Schelch K, Sinn K, Mosleh B, Hoda MA, et al: Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. J Exp Clin Cancer Res. 42:272023. View Article : Google Scholar : PubMed/NCBI
34	Markowitz D, Goff S and Bank A: A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol. 62:1120–1124. 1988. View Article : Google Scholar : PubMed/NCBI
35	Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG and Kassem M: Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 20:592–596. 2002. View Article : Google Scholar : PubMed/NCBI
36	Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, et al: Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS One. 10:e01312412015. View Article : Google Scholar : PubMed/NCBI
37	Puig T, Turrado C, Benhamú B, Aguilar H, Relat J, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A, Haro D, et al: Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res. 15:7608–1765. 2009. View Article : Google Scholar : PubMed/NCBI
38	Turrado C, Puig T, García-Cárceles J, Artola M, Benhamú B, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A, Haro D, et al: New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem. 55:5013–5023. 2012. View Article : Google Scholar : PubMed/NCBI
39	Alwarawrah Y, Hughes P, Loiselle D, Carlson DA, Darr DB, Jordan JL, Xiong J, Hunter LM, Dubois LG, Thompson JW, et al: Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 23:678–688. 2016. View Article : Google Scholar : PubMed/NCBI
40	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
41	Hanahan D: Hallmarks of cancer: New dimensions. Cancer Discov. 12:31–46. 2022. View Article : Google Scholar : PubMed/NCBI
42	Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, et al: Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian High-Grade serous carcinomas. Cancer Res. 76:796–804. 2016. View Article : Google Scholar :
43	Pua TL, Wang FQ and Fishman DA: Roles of LPA in ovarian cancer development and progression. Future Oncol. 5:1659–1673. 2009. View Article : Google Scholar : PubMed/NCBI
44	Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, et al: The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J Pathol. 227:136–145. 2012. View Article : Google Scholar : PubMed/NCBI
45	Kim S, Kim B and Song YS: Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 107:1173–1178. 2016. View Article : Google Scholar : PubMed/NCBI
46	Ghoneum A, Afify H, Salih Z, Kelly M and Said N: Role of tumor microenvironment in ovarian cancer pathobiology. Oncotarget. 9:22832–22849. 2018. View Article : Google Scholar : PubMed/NCBI
47	Impheng H, Pongcharoen S, Richert L, Pekthong D and Srisawang P: The selective target of capsaicin on FASN expression and de novo fatty acid synthesis mediated through ROS generation triggers apoptosis in HepG2 cells. PLoS One. 9:e1078422014. View Article : Google Scholar : PubMed/NCBI
48	Lou E, Vogel RI, Hoostal S, Klein M, Linden MA, Teoh D and Geller MA: Tumor-Stroma proportion as a predictive biomarker of resistance to Platinum-Based chemotherapy in patients with ovarian cancer. JAMA Oncol. 5:1222–1224. 2019. View Article : Google Scholar : PubMed/NCBI
49	Romanauska A and Köhler A: Reprogrammed lipid metabolism protects inner nuclear membrane against unsaturated fat. Dev Cell. 56:2562–2578. 2021. View Article : Google Scholar : PubMed/NCBI
50	Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniels VW, Machiels J, et al: De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70:8117–8126. 2010. View Article : Google Scholar : PubMed/NCBI
51	Nieman KM, Romero IL, Van Houten B and Lengyel E: Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI
52	Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, et al: Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 37:2285–2301. 2018. View Article : Google Scholar : PubMed/NCBI
53	Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O and Lengyel E: Adipocyte-Induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res. 80:1748–1761. 2020. View Article : Google Scholar : PubMed/NCBI
54	Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F, Fukuda K, Hirota S, Sugai T, et al: Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 130:387–398. 2011. View Article : Google Scholar
55	Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, Matei D and Cheng JX: Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 20:303–314.e5. 2017. View Article : Google Scholar : PubMed/NCBI
56	Grunt TW and Valent P: Increased lipid desaturation and ovarian cancer stem cells. Transl Cancer Res. 6(Suppl 3): S472–S475. 2017. View Article : Google Scholar
57	Cao Y: Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 129:3006–3017. 2019. View Article : Google Scholar : PubMed/NCBI
58	Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, et al: Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget. 9:24787–24800. 2018. View Article : Google Scholar : PubMed/NCBI
59	Wong A, Chen S, Yang LK, Kanagasundaram Y and Crasta K: Lipid accumulation facilitates mitotic slippage-induced adaptation to anti-mitotic drug treatment. Cell Death Discov. 4:1092018. View Article : Google Scholar : PubMed/NCBI
60	Park R, Jang M, Park YI, Park Y, Namkoong S, Lee JI and Park J: Elevated levels of CTRP1 in obesity contribute to tumor progression in a p53-Dependent manner. Cancers (Basel). 13:36192021. View Article : Google Scholar : PubMed/NCBI
61	Garcia DI, Hurst KE, Bradshaw A, Janakiraman H, Wang C and Camp ER: High-fat diet drives an aggressive pancreatic cancer phenotype. J Surg Res. 264:163–172. 2021. View Article : Google Scholar : PubMed/NCBI
62	Lombardi S, Goldman AR, Tang HY, Kossenkov AV, Liu H, Zhou W, Herlyn M, Lin J and Zhang R: Targeting fatty acid reprogramming suppresses CARM1-expressing ovarian cancer. Cancer Res Commun. 3:1067–1077. 2023. View Article : Google Scholar : PubMed/NCBI
63	Bao J, Zhu L, Zhu Q, Su J, Liu M and Huang W: SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer. Oncol Lett. 12:2409–2416. 2016. View Article : Google Scholar : PubMed/NCBI
64	Nie LY, Lu QT, Li WH, Yang N, Dongol S, Zhang X and Jiang J: Sterol regulatory element-binding protein 1 is required for ovarian tumor growth. Oncol Rep. 30:1346–1354. 2013. View Article : Google Scholar : PubMed/NCBI